Baird Initiates Coverage on Abbott Laboratories (ABT) Stock with Outperform Rating

The company's diagnostics, nutrition, and established pharmaceutical offerings heighten Abbott Laboratories (NYSE:ABT)'s scope passim the healthcare spectrum. As per the firm, determination is simply a clearer way to upside successful FY 2027 and FY 2028, with caller products and denotation opportunities layering in, and Exact Sciences integration and synergies contributing to the results.

In a antithetic update, Evercore ISI expert Vijay Kumar reduced the firm's terms nonsubjective connected Abbott Laboratories (NYSE:ABT)'s banal to $112 from $120 and maintained an "Outperform" rating. The firm's Q2 preview for MedTech, Life Sciences Tools, and Diagnostics demonstrates steadfast process volumes arsenic good arsenic capex trends passim the sector.

Abbott Laboratories (NYSE:ABT) is engaged successful discovering, developing, manufacturing, and selling wellness attraction products.

While we admit the imaginable of ABT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey connected Google News.